DURECT Corporation (DRRX) is pursuing the use of POSIMIR (extended release bupivacaine solution) for post-operative pain and DUR-928, a sulfated oxysterol, for several indications. POSIMIR was in Phase 3 clinical trials in 2010, and an NDA was submitted in April, 2013. A Complete Response Letter was received in 2014 indicating that multiple safety trials would be required, though this was later reduced to one trial for safety and efficacy based on a narrower indication. In 2017, it was announced that the drug did not meet the the primary efficacy endpoint. While management